PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 6.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,856,127 | -40.7% | 5,131,433 | -13.6% | 0.00% | -50.0% |
Q2 2023 | $26,730,990 | -48.4% | 5,940,220 | -34.7% | 0.00% | 0.0% |
Q1 2023 | $51,832,128 | +87.0% | 9,093,356 | +98.1% | 0.00% | -33.3% |
Q4 2022 | $27,721,135 | -9.6% | 4,589,592 | -1.1% | 0.00% | 0.0% |
Q3 2022 | $30,660,000 | +36.5% | 4,638,547 | +7.8% | 0.00% | +50.0% |
Q2 2022 | $22,461,000 | -39.4% | 4,302,969 | -19.9% | 0.00% | -33.3% |
Q1 2022 | $37,065,000 | -49.9% | 5,371,907 | -9.5% | 0.00% | -40.0% |
Q4 2021 | $73,939,000 | -66.5% | 5,938,933 | -15.8% | 0.01% | -70.6% |
Q3 2021 | $220,489,000 | +17.5% | 7,055,666 | +7.7% | 0.02% | +13.3% |
Q2 2021 | $187,598,000 | -30.8% | 6,552,499 | +4.8% | 0.02% | -34.8% |
Q1 2021 | $270,904,000 | -8.6% | 6,252,107 | +48.5% | 0.02% | -11.5% |
Q4 2020 | $296,295,000 | +228.8% | 4,209,963 | +34.6% | 0.03% | +188.9% |
Q3 2020 | $90,109,000 | – | 3,128,384 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |